Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab

详细信息    查看全文

• 作者：Niklas T. Baerlecken (1)
  Reinhold E. Schmidt (1)
  
• 关键词：Cryoglobulinemia ; Leukocytoclastic vasculitis ; Rituximab
• 刊名：Clinical Rheumatology
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：32
• 期：1/suppl
• 页码：19-20
• 全文大小：105KB
• 参考文献：1. Boris AC et al (2006) Non-hepatitis C virus cryoglobulinemic vasculitis: a case series of nine patients. Rev Bras Rheumatol 46(5):310-14 CrossRef
  2. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57(5):775-88 CrossRef
  3. Cacoub P, Sene D et al (2007) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 67(3):283-87 CrossRef
  4. Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983-89 CrossRef
  5. Dervite J et al (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. NEJM 344(1):68-9 CrossRef
  6. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P et al (1980) Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69(2):287-08 CrossRef
  7. Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M, Napoli F, Sena LM (2008) Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 34(1):111-7. Review
  8. Rocatello D, Sena LM et al (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19(12):3054-061 CrossRef
  9. Saadoun D, Cacoub P et al (2008) Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Ann Rheum Dis 111(11):5334-341
  10. Sansanno D, Dammacco F et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101(10):3818-826 CrossRef
  11. Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, Wilke N, Schmidt RE, Jacobs R (2009) Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 60(12):3563-71
  12. Zaja F, De Vita S, Mazzaro C et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-834 CrossRef
  
• 作者单位：Niklas T. Baerlecken (1)
  Reinhold E. Schmidt (1)
  
  1. Clinic for Immunology and Rheumatology, Medical School of Hanover, Carl-Neuberg-Str., 1 30625, Hanover, Germany
  
• ISSN：1434-9949

文摘

We report about a 39-year-old female patient with severe essential mixed cryoglobulinemia of type III with leukocytoclastic vasculitis. The patient was admitted into our hospital with mesenteric lymphangiitis, which caused enteral perforation, sepsis, and pneumonia. Cryoglobulins, cryocrit, Ig-titers, and biopsy were positive for mixed cryoglobulinemia type III. We detected no signs of hepatitis C, B, or any other infectious disease. At first, disease activity could be kept under control with high doses of glucocorticoids and multiple cyclophosphamide pulses. However, after therapy with three pulses of rituximab, steroids were stopped, and the patient has not presented any symptoms for 2?years. Therefore, we suggest that rituximab affected her disease rapidly and effectively. In conclusion, rituximab is an alternative therapy for mixed cryoglobulinemia of type III with leukocytoclastic vasculitis.